These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 26581202)

  • 1. A Novel Immune Marker Model Predicts Oncological Outcomes of Patients with Colorectal Cancer.
    Chen Y; Yuan R; Wu X; He X; Zeng Y; Fan X; Wang L; Wang J; Lan P; Wu X
    Ann Surg Oncol; 2016 Mar; 23(3):826-32. PubMed ID: 26581202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A High RORγT/CD3 Ratio is a Strong Prognostic Factor for Postoperative Survival in Advanced Colorectal Cancer: Analysis of Helper T Cell Lymphocytes (Th1, Th2, Th17 and Regulatory T Cells).
    Yoshida N; Kinugasa T; Miyoshi H; Sato K; Yuge K; Ohchi T; Fujino S; Shiraiwa S; Katagiri M; Akagi Y; Ohshima K
    Ann Surg Oncol; 2016 Mar; 23(3):919-27. PubMed ID: 26564244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. OX40 expression enhances the prognostic significance of CD8 positive lymphocyte infiltration in colorectal cancer.
    Weixler B; Cremonesi E; Sorge R; Muraro MG; Delko T; Nebiker CA; Däster S; Governa V; Amicarella F; Soysal SD; Kettelhack C; von Holzen UW; Eppenberger-Castori S; Spagnoli GC; Oertli D; Iezzi G; Terracciano L; Tornillo L; Sconocchia G; Droeser RA
    Oncotarget; 2015 Nov; 6(35):37588-99. PubMed ID: 26439988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
    Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
    JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aldehyde Dehydrogenase 1 Expression Predicts Chemoresistance and Poor Clinical Outcomes in Patients with Locally Advanced Cervical Cancer Treated with Neoadjuvant Chemotherapy Prior to Radical Hysterectomy.
    Xie Q; Liang J; Rao Q; Xie X; Li R; Liu Y; Zhou H; Han J; Yao T; Lin Z
    Ann Surg Oncol; 2016 Jan; 23(1):163-70. PubMed ID: 25916979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative Neutrophil-to-Lymphocyte Ratio is a Better Prognostic Serum Biomarker than Platelet-to-Lymphocyte Ratio in Patients Undergoing Resection for Nonmetastatic Colorectal Cancer.
    Choi WJ; Cleghorn MC; Jiang H; Jackson TD; Okrainec A; Quereshy FA
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S603-13. PubMed ID: 25900206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA Hypermethylation of SHISA3 in Colorectal Cancer: An Independent Predictor of Poor Prognosis.
    Tsai MH; Chen WC; Yu SL; Chen CC; Jao TM; Huang CY; Tzeng ST; Yen SJ; Yang YC
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1481-9. PubMed ID: 25968618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CEA change after neoadjuvant chemotherapy including bevacizumab and clinical outcome in patients undergoing liver resection for colorectal liver metastases.
    Stremitzer S; Stift J; Graf A; Singh J; Starlinger P; Gruenberger B; Tamandl D; Gruenberger T
    Ann Surg Oncol; 2015 Apr; 22(4):1315-23. PubMed ID: 25323471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiogenesis-Related Markers and Prognosis After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Metastatic Colorectal Cancer.
    de Cuba EM; de Hingh IH; Sluiter NR; Kwakman R; Coupé VM; Beliën JA; Verwaal VJ; Meijerink WJ; Delis-van Diemen PM; Bonjer HJ; Meijer GA; Te Velde EA
    Ann Surg Oncol; 2016 May; 23(5):1601-8. PubMed ID: 26727921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protocadherin 10 suppresses tumorigenesis and metastasis in colorectal cancer and its genetic loss predicts adverse prognosis.
    Jao TM; Tsai MH; Lio HY; Weng WT; Chen CC; Tzeng ST; Chang CY; Lai YC; Yen SJ; Yu SL; Yang YC
    Int J Cancer; 2014 Dec; 135(11):2593-603. PubMed ID: 24740680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of KRAS Mutation on Long-Term Outcomes of Patients Undergoing Hepatic Resection for Colorectal Liver Metastases.
    Margonis GA; Spolverato G; Kim Y; Karagkounis G; Choti MA; Pawlik TM
    Ann Surg Oncol; 2015 Dec; 22(13):4158-65. PubMed ID: 26077912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of the lymph node ratio in stage IV colorectal cancer patients who have undergone curative resection.
    Ozawa T; Ishihara S; Nishikawa T; Tanaka T; Tanaka J; Kiyomatsu T; Hata K; Kawai K; Nozawa H; Kanazawa T; Kazama S; Yamaguchi H; Sunami E; Kitayama J; Watanabe T
    Ann Surg Oncol; 2015 May; 22(5):1513-9. PubMed ID: 25398278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX.
    Lee DW; Kim KJ; Han SW; Lee HJ; Rhee YY; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY
    Ann Surg Oncol; 2015 Jan; 22(1):187-94. PubMed ID: 24889488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer.
    Iinuma H; Watanabe T; Mimori K; Adachi M; Hayashi N; Tamura J; Matsuda K; Fukushima R; Okinaga K; Sasako M; Mori M
    J Clin Oncol; 2011 Apr; 29(12):1547-55. PubMed ID: 21422427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stratification of chemotherapy-treated stage III colorectal cancer patients using multiplexed imaging and single-cell analysis of T-cell populations.
    Stachtea X; Loughrey MB; Salvucci M; Lindner AU; Cho S; McDonough E; Sood A; Graf J; Santamaria-Pang A; Corwin A; Laurent-Puig P; Dasgupta S; Shia J; Owens JR; Abate S; Van Schaeybroeck S; Lawler M; Prehn JHM; Ginty F; Longley DB
    Mod Pathol; 2022 Apr; 35(4):564-576. PubMed ID: 34732839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic significance of tryptophanyl-tRNA synthetase in colorectal cancer.
    Ghanipour A; Jirström K; Pontén F; Glimelius B; Påhlman L; Birgisson H
    Cancer Epidemiol Biomarkers Prev; 2009 Nov; 18(11):2949-56. PubMed ID: 19900940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic significance and relationship with body composition of CCR7-positive cells in colorectal cancer.
    Malietzis G; Lee GH; Bernardo D; Blakemore AI; Knight SC; Moorghen M; Al-Hassi HO; Jenkins JT
    J Surg Oncol; 2015 Jul; 112(1):86-92. PubMed ID: 26179425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inverse effect of mucinous component on survival in stage III colorectal cancer.
    Ooki A; Akagi K; Yatsuoka T; Asayama M; Hara H; Yamamoto G; Nishimura Y; Yamaguchi K
    J Surg Oncol; 2014 Dec; 110(7):851-7. PubMed ID: 25111953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Smad4 inactivation predicts for worse prognosis and response to fluorouracil-based treatment in colorectal cancer.
    Kozak MM; von Eyben R; Pai J; Vossler SR; Limaye M; Jayachandran P; Anderson EM; Shaffer JL; Longacre T; Pai RK; Koong AC; Chang DT
    J Clin Pathol; 2015 May; 68(5):341-5. PubMed ID: 25681512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between GWAS-identified genetic variations and disease prognosis for patients with colorectal cancer.
    Kang BW; Jeon HS; Chae YS; Lee SJ; Park JY; Choi JE; Park JS; Choi GS; Kim JG
    PLoS One; 2015; 10(3):e0119649. PubMed ID: 25799222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.